Efficacy and tolerance of interferon‐α in the treatment of chronic Hepatitis C in end‐stage renal disease patients on hemodialysis

Abstract

IFN-alpha monotherapy for hepatitis C in dialysis patients shows a high frequency of adverse effects. However, the SVR is high (34%) in patients who complete treatment, emphasizing the importance of careful selection and close follow-up in order to minimize and control possible side effects.